Johnson & Johnson vs Verastem
Johnson & Johnson (JNJ) and Verastem (VSTM) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $651B
- Last close
- $270.47
- 12 months
- +33.2%
- Market value
- $798M
- Last close
- $6.33
- 12 months
- −35.5%
At a glance
- The biggest part of Johnson & Johnson's revenue is Innovative Medicine, 64% of the total in its last annual report.
- By market value, Johnson & Johnson ($651.1B) is about 816 times Verastem ($798M).
- Over the last 12 months Johnson & Johnson's share price moved +33.2% and Verastem's −35.5%; against the S&P 500 that is +27.5 points and −41.2 points.
- In their last fiscal years Johnson & Johnson kept 28.5% of revenue as net income and Verastem -677.6%.
- In the last 90 days insiders reported 0 open-market purchases at Johnson & Johnson and 0 at Verastem; members of Congress disclosed 5 trades in Johnson & Johnson and 0 in Verastem.
- Next results: Johnson & Johnson Jan 26, 2027, Verastem Mar 2, 2027.
How each one makes money: Johnson & Johnson revenue
Share prices on one chart
Johnson & Johnson and Verastem, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Johnson & Johnson JNJNYSE · Pharmaceuticals | Verastem VSTMNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $651B | $798M |
| Revenue, last fiscal year | $94.2B | $30.9M |
| Net income, last fiscal year | $26.8B | −$209M |
| Net marginNet income as a share of revenue | 28.5% | -677.6% |
| Free cash flow | $19.7B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Johnson & Johnson against
Common questions
How is Johnson & Johnson different from Verastem?
Johnson & Johnson (JNJ) is in Pharmaceuticals on NYSE, with $94.2B of revenue in its last fiscal year and a net margin of 28.5%. Verastem (VSTM) is in Pharmaceutical Preparations on NASDAQ, with $30.9M of revenue in its last fiscal year and a net margin of -677.6%. The biggest part of Johnson & Johnson's revenue is Innovative Medicine, 64% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Johnson & Johnson and Verastem compare in size?
Johnson & Johnson has the larger market value: Johnson & Johnson $651B and Verastem $798M, at the last close.
Whose share price rose more over the last 12 months, JNJ or VSTM?
Over the last 12 months Johnson & Johnson moved +33.2% and Verastem −35.5%. Past price moves say nothing about the future.
Which has had more insider buying, Johnson & Johnson or Verastem?
Since 2006, Verastem insiders reported 104 open-market purchases against 25 for Johnson & Johnson. These are counts of what was filed, not a view on either stock.
Do members of Congress trade JNJ or VSTM?
In the last 12 months, members of Congress disclosed 24 trades in Johnson & Johnson (JNJ) and 0 in Verastem (VSTM).
When did insiders last buy JNJ and VSTM?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Johnson & Johnson pageVerastem pageRare insider trades this weekAll comparisons
https://oqro.io/compare/jnj-vs-vstm







